Uploaded April 2023 | Updated September 2026, 2 weeks ago
More information: hololifesummit.com
Join HOLOLIFE Academy: skool.com/hololife-academy/about
Biochemist Shawn Wells discusses the transformative potential of psychedelics for mental health, moving beyond traditional SSRI treatments to explore neuroplasticity and neurotransmitter regulation. The video covers clinical study results for psilocybin, MDMA, and ketamine, emphasizing the critical role of facilitated psychotherapy and integration. Wells introduces specialized protocols like 'echo dosing' and supplement stacking to optimize the therapeutic journey and long-term recovery from depression and PTSD.
- Traditional antidepressants (SSRIs) often fail to address the root causes of rising global depression and PTSD rates.
- Clinical studies show psilocybin can lead to a 50% reduction in depression symptoms for a majority of participants.
- MDMA-assisted therapy has demonstrated a 67% success rate in removing PTSD diagnostic criteria for patients.
- Ketamine acts as a fast-acting antidepressant by dissociating patients from their trauma and ego-locked identities.
- Psychedelics promote neuroplasticity by increasing Brain-Derived Neurotrophic Factor (BDNF) and physical neuron growth.
- Effective psychedelic therapy requires 'set and setting,' including preparatory sessions and professional facilitation.
- Integration work is essential to prevent post-journey distress and to turn insights into lasting life changes.
- The 'serotonin theory' is an oversimplification; mood regulation involves a complex web of neurotransmitters like glutamate and GABA.
- Echo dosing is a novel concept involving microdoses taken after a major journey to assist in the integration process.
- Psychedelics help reduce systemic and neurological inflammation while improving overall immune system function.
More information: hololifesummit.com
Join HOLOLIFE Academy: skool.com/hololife-academy/about
Biochemist Shawn Wells discusses the transformative potential of psychedelics for mental health, moving beyond traditional SSRI treatments to explore neuroplasticity and neurotransmitter regulation. The video covers clinical study results for psilocybin, MDMA, and ketamine, emphasizing the critical role of facilitated psychotherapy and integration. Wells introduces specialized protocols like 'echo dosing' and supplement stacking to optimize the therapeutic journey and long-term recovery from depression and PTSD.
- Traditional antidepressants (SSRIs) often fail to address the root causes of rising global depression and PTSD rates.
- Clinical studies show psilocybin can lead to a 50% reduction in depression symptoms for a majority of participants.
- MDMA-assisted therapy has demonstrated a 67% success rate in removing PTSD diagnostic criteria for patients.
- Ketamine acts as a fast-acting antidepressant by dissociating patients from their trauma and ego-locked identities.
- Psychedelics promote neuroplasticity by increasing Brain-Derived Neurotrophic Factor (BDNF) and physical neuron growth.
- Effective psychedelic therapy requires 'set and setting,' including preparatory sessions and professional facilitation.
- Integration work is essential to prevent post-journey distress and to turn insights into lasting life changes.
- The 'serotonin theory' is an oversimplification; mood regulation involves a complex web of neurotransmitters like glutamate and GABA.
- Echo dosing is a novel concept involving microdoses taken after a major journey to assist in the integration process.
- Psychedelics help reduce systemic and neurological inflammation while improving overall immune system function.
